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Nutritional supplements and conventional medicine; what should
the physician know?
Geoffrey P. Webb
School of Health and Bioscience, University of East London, Romford Road, London E15 4LZ, UK
Almost anything that is swallowed in pill or potion form that is not a licensed medicine is, by
default, legally classified as a dietary supplement. The present paper is an overview of
supplement use and is intended to provide a logical framework for their discussion. Five major
supplement categories are identified: essential micronutrients; other metabolites that have
vitamin-like roles; natural oils; natural plant or animal extracts; antioxidants, which span the
other categories. Supplement usage is also classified into broad categories. Examples of each
supplement category and usage are briefly discussed. Some potential hazards of supplement use
are also outlined; many substances in supplements are either not found in normal UK diets or
consumed in much greater amounts than would be found in food. Many supplements are used
for pharmaceutical purposes and sold as supplements to avoid the expense of acquiring a
medicinal licence and to avoid the stricter quality-control regulations that apply to medicines.
The use of supplements to ensure nutritional adequacy and as possible conditionally-essential
nutrients is briefly discussed, as is their essentially pharmaceutical use for the prevention and
alleviation of disease. There is critical discussion of whether the use of antioxidant supplements
is justified or even if it is reasonable to promote a particular food on the basis of antioxidant
content alone. Much of the research on supplements is reductionist, commercially sponsored or
has other weaknesses; so, despite decades of use and research there is still uncertainty about
their efficacy in many cases.
Dietary supplements: Micronutrient deficiencies: Antioxidants: Conditionally-essential
nutrients
Supplements are often taken for pharmaceutical rather
than nutritional reasons, i.e. to prevent or treat disease,
but they are sold as dietary supplements to avoid the
need to demonstrate their safety and efficacy to the
UK Medicines and Healthcare Products Regulatory
Authority. A dietary supplement is subject to food laws
and so it is not permitted to make any medicinal claims
relating to treatment or prevention of specific diseases, but
more general health claims, e.g. ‘helps to maintain a
healthy heart’ or ‘helps to maintain healthy joints’, can be
made. In practice, medicinal claims can be brought to the
attention of the supplement-buying public, and supple-
ments can also be obtained from suppliers who are outside
of British and EU jurisdiction, e.g. from the Channel
Islands.
Before a medicinal licence is granted the safety and
efficacy of the product must be demonstrated. Dietary
supplements are permitted unless there is evidence of
harm. A supplement may continue to be sold despite evi-
dence that it is ineffective and possibly even when there is
evidence of negative long-term effects.
Several all-embracing definitions of dietary supplements
have been made(1). Rather than another definition, five
categories have been identified into which most supple-
ments fit:
1. single or combined vitamins and minerals;
2. organic compounds that are normal body metabolites
but not recognised as essential nutrients because
they are synthesised endogenously, e.g. glucosamine,
S-adenosylmethionine, L-carnitine and ubiquinone 10;
3. natural extracts that may contain bioactive substances
(e.g. garlic (Allium sativum L.), soyabean, Ginkgo
biloba L., ginseng (Panax spp.));
Abbreviation: RNI, reference nutrient intake.
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4. natural fats and oils such as fish oil and evening
primrose (Oenothera biennis L.) oil;
5. antioxidants, which span the other categories listed(2);
thus, vitamin E, b-carotene, lycopene, Se, ubiquinone
10 and extracts of green tea and milk thistle (Silybum
marianum (L.) Gaertner) are all marketed as anti-
oxidants.
Uses of supplements
Supplements are taken for many specific purposes, but
most are covered by four broad headings: (1) to ensure
micronutrient adequacy; (2) to compensate for some
(perceived) increase in need or defective handling of a
nutrient or metabolite; (3) to prevent or treat illness; either
to alleviate or reverse existing conditions or to reduce the
long-term risk of developing a chronic disease; (4) to
improve athletic performance.
Possible adverse consequences of supplement use
Supplements may have toxic effects per se; this risk will
increase with dose and duration of use.
‘All substances are poisonous; there is none which is
not a poison. The right dose differentiates a poison
and a remedy’ Paracelsus 1493–1541
Even essential nutrients such as retinol and cholecalciferol
have toxic and potentially-fatal effects at high doses. Fe
poisoning is one of the most common causes of accidental
poisoning in children.
If a micronutrient supplement is taken in order to ensure
nutritional adequacy then the dose is likely to be based on
the RDA and comparable with the amounts consumed in
a normal diet. When supplements are taken for pharma-
ceutical purposes then pharmacological doses may be
taken for extended periods. Cod liver oil supplements
have traditionally been used to ensure vitamin A and D
adequacy, but when taken to boost intakes of long-chain
n-3 PUFA these fat-soluble vitamins may now reduce the
amount of oil that can be taken without risking vitamin
overdose. Many substances in natural extracts are not
normal dietary constituents.
Even if a substance sold as a supplement is not harmful
per se, because of poor quality control it may be con-
taminated with other harmful substances such as heavy
metals. Synthetic drugs have been surreptitiously added to
some supplements, particularly ethnic medicines(3). There
is no guarantee of their identity, purity, strength and bio-
availability, and a high proportion of supplements sold in
the USA fail on one or more of these criteria. Of thirty-five
multinutrient preparations eleven were found to fail on
these criteria, including one aimed at children that con-
tained excessive amounts of vitamin A and one for women
that was contaminated with Pb(4) (part of the extensive
testing performed by ConsumerLab (www.consumerlab.
com), an independent testing organisation that performs
testing of supplements on the American market). Natural
extracts pose particular problems because the ‘active’
ingredient is often uncertain and even when standardised
they may not contain the claimed amount of ‘active’
ingredient. Samples of St John’s wort (Hypericum perfor-
atum) tablets purchased in London were found to contain
between one-third and two-thirds of the stated hypericin
content, and hypericin is probably not the ‘active’ com-
pound, i.e. these extracts were probably standardised to the
wrong ingredient and contained less than the claimed
content of this ingredient(5). Preparations of Spirulina
geitleri have been marketed as a source of vitamin B12
suitable for vegans, but the vitamin B12-like compound
found in this alga is not biologically active in mammals(6).
Supplements can be used as an easy alternative to
making more difficult and more useful changes in diet and
lifestyle. Individuals may take an antioxidant supplement
to ‘soak up’ the extra free radicals generated by exposure
to cigarette smoke or take milk thistle to protect their liver
from alcohol abuse or take plant extracts rather than eat
five portions of fruit and vegetables daily.
Substances in supplements may interact with prescribed
medicines and either reduce their effectiveness or even
increase their potency. For example, in March 2000 the
UK Department of Health issued a warning that St John’s
wort extracts may reduce the effectiveness of several pre-
scription drugs and may increase the effects of commonly-
prescribed antidepressants(7).
Supplements may be an expensive way of obtaining
common food components; use of multiple supplements
may divert money from more useful purposes such as food
or heating. They tend to introduce a medical perspective to
eating and undermine its social, cultural and pleasurable
aspects.
Vitamins and minerals
Micronutrient adequacy in the UK
Micronutrient supplements are often dismissed as a waste
of money because micronutrient deficiencies rarely occur
in healthy affluent populations and because supplements
are usually taken by those who need them least. Supple-
ment use certainly is concentrated in those with the highest
nutrient intakes from food(8,9) and declines with declining
social class(10). However, surveys of British adults(8),
schoolchildren(11) and elderly adults(12) all suggest that any
assumption of general micronutrient adequacy in the UK
may be too complacent. Table 1 shows an analysis of the
vitamin adequacy of British adults(13). Average intakes of
the whole sample seem reassuring because they are all
above the reference nutrient intake (RNI) and usually well
above it. Average intakes are lower in the youngest age-
group (19–24 years) and the average vitamin A intake of
this group is well below the RNI. Table 1 also shows that
substantial numbers of adults have recorded vitamin
intakes below the lower RNI or have biochemical indica-
tions of unsatisfactory status (1% of British adults repre-
sent >250 000 individuals). The lower RNI is theoretically
sufficient for 2.5% of the population, but low intakes will
not be restricted to those with low requirements. Other
examples of unsatisfactory micronutrient intakes or bio-
chemical status in British adults and children are listed in
Table 2.
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The assumption that unsatisfactory micronutrient
intakes are confined to those with unusual dietary choices
or special social or medical problems may be too opti-
mistic. Falling energy intakes and high consumption of
low-nutrient-density foods increase the risk of micro-
nutrient inadequacies. Dietary improvements and increased
energy expenditure encouraged by effective health-
promotion programmes would be the ideal solution to this
problem. However, properly targeted use of moderate
micronutrient supplements could be a useful, if not ideal,
short-term adjunct to dietary improvement.
Other ‘uses’ of vitamin and mineral supplements
Micronutrients may be taken for other reasons at doses of
several multiples of the RNI or RDA: (1) vitamin C is
widely taken in doses of ten to 100 times the RNI in the
hope that it will prevent colds and flu. A meta-analysis of
twenty-nine trials found no evidence of a preventative
effect or benefits of large doses taken at the onset of
cold symptoms(14); (2) vitamin B6 has been widely taken
by women to alleviate premenstrual symptoms. Doses
of £100 mg/d may be used compared with average UK
intakes of 2 mg/d. A safe upper limit of 10 mg/d has been
suggested because of evidence from animal studies that
higher doses may be neurotoxic(15).
Very large supplements (20 · RNI) of folic acid taken
before conception and in early pregnancy greatly reduce
the recurrence of neural-tube defects in women with
a previously-affected pregnancy(16). More modest doses
reduce the rate of first occurrence of neural-tube
defects(17). Extra folic acid may ameliorate the effects of
a genetic variation in a folate-dependent enzyme that pre-
disposes to neural-tube defects(18). All sexually-active
fertile British women are advised to take folic acid sup-
plements (2 · RNI) and advice to take peri-conceptual
folic acid supplements dates back to 1992(19).
In 2000 a UK expert group(20) recommended that
flour should be fortified with 2400mg folic acid/kg, but
this recommendation has not yet been implemented.
Campaigns to encourage the use of folic acid supplements
have had no measurable impact on the incidence of neural-
tube defects even after 6 years duration, but rates have
fallen sharply and immediately after the introduction of
food fortification in the USA, Canada and Chile(21). To be
maximally effective extra folic acid needs to be taken in
the peri-conceptual period, particularly by those with
the lowest dietary intakes; ideally, supplementation should
Table 2. Some further examples of apparently unsatisfactory micronutrient intakes or biochemical status in the British population(11–13)
25% of women (19–64 years) had recorded Fe intakes below the LRNI and 11% had serum ferritin levels indicative of low Fe stores
(corresponding values in those aged 19–24 years were 42% and 16% respectively)
8% of women aged 19–24 years had recorded Ca intakes below the LRNI
Approximately 20% of adolescent girls and 12% of boys had recorded vitamin A intakes below the LRNI
Biochemical evidence of poor vitamin D status was found in 13% of 11–18 year olds with higher numbers in the winter months
50% of older girls had Fe intakes below the LRNI appropriate for starting menstruation and 27% had serum ferritin levels indicative
of low Fe stores
One-fifth of older girls had riboflavin intakes below the LRNI
Approximately 10% of elderly adults had serum ferritin levels indicative of low Fe stores
8% of free-living elderly adults and 37% of those living in institutions had biochemical evidence of poor vitamin D status
30–40% of elderly adults had low biochemical status for folate
14% of the independent elderly and 40% of the institutionalised elderly had biochemical evidence of poor vitamin C status
High proportions of adults, children and elderly adults had recorded intakes of one or more of the minerals not already listed that
were below the LRNI
LRNI, lower reference nutrient intake.
Table 1. The vitamin adequacy of adult British diets aged 19–64 years(13)
Age-group (years). . . . . .
Average intake (% RNI) Percentage below LRNI
Percentage below
biochemical threshold
Men Women Men Women Men Women
19–64 19–24 19–64 19–24 19–64 19–24 19–64 19–24 19–64 19–24 19–64 19–24
Vitamin A (retinol equivalents) 130 80 112 78 7 16 9 19 0 0 0 0
Thiamin 214 160 193 181 1 2 1 0 3 0 1 0
Riboflavin 162 129 146 126 3 8 8 15 66 82 66 77
Niacin equivalents 268 232 257 246 0 0 1 2
Vitamin B6 204 189 169 165 1 0 2 5 10 4 11 12
Vitamin B12 431 296 319 266 0 1 1 1 2 0 4 5
Folate* 172 151 125 114 0 2 2 3 4 13 5 8
Vitamin C 209 162 202 170 0 0 0 1 5 7 3 4
Vitamin D† (mg) 3.7 2.9 2.8 2.3 – – – – 14 24 15 28
RNI, reference nutrient intake; LRNI, lower RNI.
*Biochemical value is erythrocyte folate indicating marginal status.
†No adult RNI or LRNI for vitamin D; absolute values given.
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start before conception. Yet, half pregnancies are unplan-
ned and supplements are generally taken by those with
highest dietary intakes. This situation may indicate a
general weakness of any health-promotion strategy that
relies on the use of supplements.
Fortification in the UK has been delayed by safety con-
cerns, particularly that extra folic acid might mask the
haematological manifestations of vitamin B12 deficiency in
elderly adults and thus delay diagnosis until permanent
neurological damage has occurred. A safe upper limit of
1.5 mg folic acid/d has been suggested(15), which compares
with average folate intakes in the elderly of <300mg/d
and 30–40% show biochemical evidence of folate defi-
ciency(12). Folic acid supplements may also lower homo-
cysteine levels in blood, and elevated homocysteine levels
are associated with increased risk of heart disease(22). Has
justifiable caution about a fortification programme aimed at
benefiting a small minority become indecision?
Metabolites other than vitamins
Many dietary supplements are natural metabolites that
have vitamin-like biochemical functions, such as being
enzyme cofactors or precursors for the synthesis of other
biologically-important molecules.
These metabolites are not ‘essential’ because they are
synthesised endogenously. Their use as supplements im-
plies that endogenous synthesis is sometimes suboptimal,
e.g. insufficient in pathological states or for optimal health
or athletic performance. L-3,4-Dihydroxyphenylalanine
used to treat Parkinson’s disease is a good example of a
natural metabolite with proven therapeutic value.
The distinction between essential and non-essential
nutrients is not absolute. Some nutrients are termed con-
ditionally essential and ‘must be supplied exogenously to
specific populations that do not synthesise them in ade-
quate amounts’(23). These substances are only essential in
certain pathological states, in newborn infants or in indi-
viduals with certain inborn errors of metabolism. Certain
genetic defects of fatty acid metabolism or carnitine
transport make carnitine an essential nutrient. The amino
acids cysteine and tyrosine are essential for premature
babies because the synthetic enzymes develop in late
gestation and they may become essential in liver cirrhosis.
Even some vitamins are only essential under some con-
ditions, e.g. vitamin D only when there is inadequate
exposure to sunlight and niacin only if supplies of trypto-
phan are limited. Deficiency syndromes are rarely seen for
some vitamins like biotin and pantothenic acid.
Glucosamine is produced endogenously by amination
of glucose and is manufactured for supplements by acid-
hydrolysis of shellfish shells. Glucosamine is a major
constituent of the polysaccharide components of proteo-
glycans in cartilage. If endogenous production of gluco-
samine is rate limiting in the production of proteoglycans
then supplements of glucosamine might accelerate pro-
teoglycan production and reduce cartilage erosion and
accelerate repair in arthritic joints. At relatively high
concentrations glucosamine has been shown to increase
the rate of proteoglycan production in cultured chondro-
cytes(24). Evidence from clinical trials does suggest that
long-term treatment with glucosamine gives more symp-
tomatic relief than a placebo and reduces narrowing of
joint space(25). At the end of a debate in London rheuma-
tologists were evenly split on whether the use of gluco-
samine supplements for osteoarthritis of the knee was
justified(26).
Creatine phosphate is a short-term energy store in
muscles that can directly re-phosphorylate ATP. Creatine
can be synthesised from other amino acids in the kidney
and liver. A typical omnivorous diet contains about 2 g
creatine/d from meat and fish. A vegetarian diet contains
almost none, but endogenous synthesis maintains the body
pool at a normal 120–160 g for adults. Creatine supple-
ments can increase the concentration of creatine phosphate
in muscle, which might be useful in boosting anaerobic
energy availability during short bursts of intense activity
such as sprinting(27).
L-Carnitine is synthesised by trimethylation of the N in
the side chain of the amino acid lysine whilst it is linked
to other amino acids by peptide bonds. Dietary meat and
fish contain carnitine but vegans who have no dietary
supply synthesise an estimated 14 mg/d in a 70 kg adult.
L-Carnitine is essential for the metabolism of long-chain
fatty acids (C‡16) that can only enter the mitochondria as
acyl carnitine esters. Carnitine also maintains a pool of free
CoA within the cell by acting as a reservoir for excess acyl
residues. High rates of production of acetyl-CoA during
catabolism would limit the availability of CoA for other
metabolic pathways, but the transfer of the acetyl group
from acetyl-CoA to L-carnitine maintains a pool of free
CoA. A genetic defect in the carnitine transporter, certain
disorders of fatty acid metabolism, haemodialysis and
anticonvulsant therapy can cause carnitine depletion that
responds to pharmacological doses of carnitine. L-Carnitine
is added to infant formula and regarded as conditionally
essential for (premature) infants(28).
Natural fats and oils
These substances include fish liver oil or fish oil,
flaxseed oil, evening primrose oil and starflower (Borago
officinalis) oil. Most oil supplements are taken either
because they are rich in n-3 PUFA or because they contain
g-linolenic acid (18:3n-6). They increase the availability
of long-chain n-3 PUFA or the availability of dihomo-
g-linolenic acid (20:3n-6; endogenous production of
dihomo-g-linolenic acid is limited by the availability of
g-linolenic acid). Increased long-chain n-3 PUFA increases
the proportion of eicosanoids produced from EPA
(20:5n-3) rather than from arachidonic acid (20:4n-6).
g-Linolenic acid increases the production of eicosanoids
from dihomo-g-linolenic acid. This change in the balance
of eicosanoid production may dampen the inflammatory
response, reduce platelet aggregation and affect other
physiological and pathological processes that are regulated
by eicosanoids. Long-chain n-3 PUFA, especially DHA
(22:6n-3), are normal components of membranes and the
high n-6 PUFA:n-3 PUFA in many modern diets may limit
the availability of DHA for optimal membrane function,
particularly in the brain.
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There are many claims for oil supplements, such as: fish
(liver) oils reduce the risk of having a heart attack, alle-
viate the symptoms of arthritis and improve behaviour and
concentration in schoolchildren; evening primrose oil and
other sources of g-linolenic acid such as starflower oil
reduce symptoms of the premenstrual syndrome, especially
mastalgia (breast pain).
Interest in the possible cardio-protective benefits of fish
oils was stimulated in 1991 by publication of a trial that
suggested that eating two weekly portions of oily fish or
taking fish oil capsules leads to reduced total mortality in
men in the 2 years after a first heart attack(29). A major
commissioned review of the effects of n-3 fatty acids from
fish oil or fish on CVD has concluded that: randomised
controlled trials of fish oil supplements suggest that they
reduce all-cause mortality and cardiovascular events in
subjects with existing diagnosed CVD; cohort studies
report a reduction in all-cause mortality, cardiovascular
deaths and myocardial infarction associated with high fish
oil consumption over 10 years(30).
Natural extracts
Many of the natural extracts sold as dietary supplements
have a long history of use as folk or herbal remedies
and are sold as dietary supplements for commercial con-
venience. Examples of such ‘supplements’ used to treat
specific medical conditions are: Agnus castus for pre-
menstrual syndrome; Saw palmetto (Serenoa repens) for
benign prostatic hyperplasia; St John’s wort for mild
depression; Echinacea (Echinacea purpurea) to boost the
immune system and prevent or treat colds and flu.
Other supplements are extracts of common food sub-
stances such as green tea, soyabeans, garlic, bilberries
(Vaccinium myrtillus) and turmeric (Curcuma longa), and
therefore have more claim to being ‘nutritional’ supple-
ments.
Usage is based on belief in the therapeutic benefits of
secondary metabolites in the extracts that may serve roles
in the plant such as: insect attractants; discouraging con-
sumption by birds, animals or insects; protection from
microbial damage; protection from UV radiation.
There are many thousands of secondary metabolites
and some are unique to a particular plant or group
of plants. They have been classified into four major
categories: terpenoids; phenols and polyphenols; alkaloids;
S-containing secondary metabolites(31).
Terpenoids
The terpenoids comprise variable numbers of C5 isoprene
units and are derived from isopentyl diphosphate:
CH2==CH(CH3)—CH2—CH2—O—P—P:
There are over 25 000 terpenoids and they can be sub-
divided into the hemiterpenes (C5), monoterpenes (C10),
sesquiterpenes (C15), diterpenes (C20), triterpenoids (C30),
tetraterpenoids (C40) and the higher terpenoids (C>40).
Several volatile oils that impart a characteristic odour
to plants such as coriander (Coriandrum sativum), lemon
and peppermint (Mentha · piperita) are monoterpenes. The
plant sterols sitosterol and stigmasterol and the saponins
are triterpenoids and the carotenoids are tetraterpenoids.
Ubiquinone is a higher terpenoid derivative.
Phenols and polyphenols
The phenols and polyphenols have at least one aromatic
ring with at least one attached hydroxyl group and they
range from simple compounds with a single aromatic ring
through stilbenes and flavonoids with two aromatic rings,
up to complex polymeric forms and conjugates such as
the flavonol glycosides. Examples include: the stilbene
trans-resveratrol famously found in red wine and produced
by the vine to combat microbial attack; flavonols such
as quercetin and kaempferol found in tea and red wine;
the isoflavones genisten and daidzein, which are phyto-
oestrogens found in soyabeans; complex polymeric flavo-
nols found in chocolate, red wines and black tea.
Alkaloids
The alkaloids are N-containing compounds synthesised
from amino acids or purine bases. Many have pharmaco-
logical activity, some are potent poisons and a number are
used as medicinal drugs. They include theobromine in
chocolate, caffeine, atropine, curare, the anti-cancer drug
vincristine, cocaine, morphine and quinine.
Sulphur-containing secondary metabolites
S-containing secondary metabolites comprise the gluco-
sinolates found in cruciferous plants such as cabbage,
rape (Brassica napus), watercress (Nasturtium nasturtium-
aquaticum L.), turnip (Brassica rapa var. rapa) and
mustard (Brassica juncea) and the S-alkylcysteine sulph-
oxides found in members of the Allium or onion family
that are synthesised from cysteine. The predominant S
compound in whole garlic is allylcysteine sulphoxide,
which is enzymically converted to allicin when the clove is
cut or crushed. Allicin is regarded as the active ingredient
in garlic supplements; it is an unstable compound and is
destroyed during cooking:
CH2==CH—CH2—S—S—CH2—CH==CH2:
Use of natural extracts
Natural extracts can undoubtedly have powerful thera-
peutic properties because they are the origin of many
medicinal drugs such as: several of the alkaloids listed
earlier; aspirin, which is derived from salicylic acid found
in willow (Salix spp.) bark; digoxin derived from the
purple foxglove (Digitalis purpurea). The assumption that
‘natural’ equates with safer is not consistent with the
potent poisons also found in natural extracts.
Garlic
Garlic supplements are taken in the belief that they will
lower plasma cholesterol levels. A major commissioned
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review of the effects of garlic supplements has found that
thirty-seven high-quality trials consistently report a small
but significant reduction in total plasma cholesterol after
1 month and 3 months but not in those eight trials that
continued to 6 months. These results suggest that any
effect of garlic on blood cholesterol is small and clinically
insignificant and may well be only transient(32).
Phyto-oestrogens
The phyto-oestrogens present in soyabean extracts have
very weak oestrogenic activity and are termed partial
agonists. In post-menopausal women with little endogen-
ous oestrogen production they may boost overall oestrogen
response, but paradoxically may reduce overall oestrogen
effects in younger women by competing for receptors with
more-potent endogenous oestrogen. They are marketed as a
‘natural’ alternative to pharmaceutical oestrogen replace-
ment in older women to alleviate acute menopausal
symptoms and to reduce bone loss and osteoporosis. In
younger women it is claimed that they may reduce breast-
cancer risks by modulating the effects of endogenous
oestrogen(33).
Antioxidants
Free radicals are very reactive chemical entities that are
produced as by-products of normal oxidative processes in
cells. They can react with and cause oxidative damage to
cellular components such as proteins, DNA, PUFA resi-
dues and complex carbohydrates. Many noxious stimuli
such as ionising radiation, cigarette smoke, sunlight or
toxic chemicals may increase free radical generation. The
cumulative damage caused to cellular components by free
radicals can lead to chronic degenerative changes and to
diseases such as cancer and atherosclerosis. Cellular anti-
oxidant mechanisms quench free radicals and repair the
damage they cause but unrepaired damage by free radicals
leads to chronic disease (see Fig. 1). Essential nutrients
such as vitamins E and C, Se and Zn have established roles
in these antioxidant mechanisms. Many other substances
found in food and supplements also have antioxidant
activity, e.g. the carotenoids in coloured fruits and
vegetables and the polyphenols found in foods such as red
wine, tea, nuts, many fruits and even chocolate. There are
frequent media reports suggesting that a particular food
or supplement can prevent cancer or chronic disease.
These claims are often based on little more than chemical
detection of an antioxidant or experimental evidence that
very high intakes of the food or supplement can reduce
some short-term measure of oxidative stress in animals,
volunteers or in vitro.
Evidence of holistic benefit from the consumption of
antioxidant supplements is sparse. The so-called ‘ACE
vitamins’ (vitamins A, C and E) are amongst the most
thoroughly tested of the antioxidants. The vitamin A
component is usually present as b-carotene because of its
low acute toxicity. The antioxidant activity of b-carotene
and other carotenoids is unrelated to their vitamin A
activity. Several expert groups have concluded that
diets rich in fruits and vegetables protect against chronic
diseases(34,35) and these are major dietary sources of
antioxidants. Observational evidence also suggests that
high intakes of b-carotene, vitamin C and/or vitamin E
are associated with reduced risk of cancer and heart dis-
ease(36–40). Such observational evidence suggests that sup-
plements of antioxidant vitamins might help to prevent
cancer and heart disease.
In contrast to the observational evidence, several large
placebo-controlled trials have suggested that supplements
of b-carotene are at best ineffective(41) or even positively
harmful, especially in smokers who show increased total
and cancer mortality(42–44). Ironically, smokers were chosen
as subjects because they were expected to gain most from
increased antioxidant intakes. Two major commissioned
reports on the effects of antioxidant supplements in the
prevention of CVD(45) and cancer(46) have concluded,
after reviewing hundreds of clinical trials, that: (1) there
is no evidence that vitamin E or vitamin C supplements
have any benefit on cardiovascular or all-cause mortality;
(2) there in no evidence that vitamin E or vitamin C sup-
plements have any beneficial effect on the incidence of
myocardial infarction or have any significant effect on
plasma lipids; (3) there is no evidence to support any
beneficial effects of vitamins C and/or E in the prevention
of new tumours, the development of colonic polyps or in
the treatment of patients with advanced cancer.
A meta-analysis of seven large controlled trials of
vitamin E supplements has found no evidence of benefits
from vitamin E supplements on all-cause, heart disease
or stroke mortality. An analysis of eight b-carotene
trials has suggested a small but significant increase in
all-cause mortality and cardiovascular deaths in those
receiving b-carotene supplements of 15–50 mg/d(47). In
1998 an expert group advised against the use of con-
centrated b-carotene supplements(35). A safe maximum
dose of b-carotene in supplements of 7 mg/d has been
suggested(15), yet tablets containing 15 mg are still on sale.
A recent highly-publicised meta-analysis has even
suggested that not only b-carotene supplements but also
retinol and vitamin E supplements may increase mortal-
ity(48). Furthermore, no evidence was found to support
any beneficial effects of b-carotene, retinol, vitamin E,
Normal mechanisms for
removal (vitamins C and E,
Se etc.). Other substances
with antioxidant activities
Stimulation (radiation,
chemicals, smoke etc.)
Excess free radicals
cause oxidative damage
Free radicals from
normal cell activities
Cumulative unrepaired
damage: cancer, heart
disease, aging etc.
Fig. 1. The free radical theory of disease.
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vitamin C or Se (either singly or in combination) on
mortality risk in primary and secondary prevention trials.
A controlled trial of large doses of vitamins C and E for
the prevention of pre-eclampsia in women with previous
history of this condition has found that it does not prevent
pre-eclampsia but does increase the rate of low-birth-
weight babies, and there was some suggestion that the
onset of pre-eclampsia occurred slightly earlier in the
antioxidant group(49).
Neutrophils are assumed to kill ingested micro-
organisms by generating an oxidative pulse of free radi-
cals. This assumption encourages a belief in the destructive
power of free radicals. It has been suggested that it is
protease enzymes produced by leucocytes, rather than free
radicals, that kill ingested microbes, and thus that the
potential toxic effects of free radicals on human cells may
have been overestimated(50).
These studies with the ‘ACE vitamins’ suggest that it
would be unwise to assume that a food or supplement is
beneficial just because it has a high chemical content of
antioxidants or reduces acute measures of oxidant stress. It
cannot be assumed that concentrated antioxidant supple-
ments are invariably safe.
Research on supplements
Many dietary supplements have been on sale for decades
and have been the subject of hundreds of research papers,
yet it is still difficult in many (most) cases to come to a
firm conclusion about the validity of claims made for
them. There may be two factors that help to explain this
situation.
If a compound shows promise of providing large and
immediate therapeutic benefits then it is likely to be
recognised and developed by the pharmaceutical industry
or orthodox medicine. Many of those that remain are thus
likely to be ineffective or have relatively small or delayed
benefits that are difficult to demonstrate conclusively.
Much of the research on supplements, and so-called
‘superfoods’, is reductionist; measuring levels of
potentially-bioactive materials, measuring in vitro effects
or measuring the effects on some acute risk marker. When
clinical trials are performed they are often flawed, e.g.
small, of short duration, incompletely double-blinded or
not properly randomised. When reading through systematic
reviews of supplement trials authors almost inevitably
comment about the low quality and size of many of the
trials, and many trials fail to meet the quality criteria for
inclusion in a meta-analysis(2). The conclusions often
change substantially when a meta-analysis is re-calculated
using only studies identified as being of the highest
quality(25,48). Much of the research on supplements and on
the health benefits of individual ‘superfoods’ seems geared
more towards attracting media attention and gaining a
commercial advantage for the research sponsor than find-
ing scientific truth.
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